Doxorubicin Hydrochloride

• Clinical trial to evaluate the effects of chemotherapy with anthracycline, after radiotherapy, in a group of pediatric and young adult patie… Ended
  2024-519135-41-00 Phase II 1 country Azienda Ospedaliera Universitaria Meyer IRCCS
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Ended
  2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SA… Ended
  2023-509498-21-00 Phase II 1 country Institut Bergonie
• TRUST : BINTRAFUSP ALFA AND DOXORUBICIN HYDROCHLORIDE IN TREATING PATIENTS WITH ADVANCED SARCOMA Ended
  2023-509497-30-00 Phase II 1 country Institut Bergonie
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended
  2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB … Ended
  2024-518847-40-00 Phase II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended
  2022-500237-92-00 Phase III 11 countries Incyte Corp.
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended
  2023-504828-25-00 Phase I/II 9 countries Genmab A/S
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended
  2023-504805-35-00 Phase I/II 10 countries Genmab A/S
• POLAR BEAR Ended
  2022-502887-19-00 Phase III 6 countries Region Skane
• Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9… Ended
  2024-511849-19-00 Phase II 2 countries Institut Jules Bordet
• Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended
  2024-511641-18-00 Phase II 1 country Fondazione Italiana Linfomi Ets
• EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended
  2023-508478-27-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d… Ended
  2022-501038-48-00 Phase II 2 countries Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended
  2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
• ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended
  2024-514275-18-00 Phase II/III 4 countries Region Skane; University Hospitals Plymouth NHS Trust
• L19TNF plus doxorubicin in patients with STS Ended
  2024-512789-32-00 Phase III 5 countries Philogen S.p.A.
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended
  2024-515499-12-00 Phase III 12 countries Universita Degli Studi Di Milano Bicocca
• SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive N… Ended
  2024-516801-22-00 Phase III 1 country Cancer Trials Ireland
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended
  2024-516996-34-00 Phase III 2 countries Unicancer
• A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended
  2023-504111-33-00 Phase II 3 countries Bristol Myers Squibb International Corporation
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep… Ended
  2024-513230-38-00 Phase III 10 countries Mural Oncology Inc.
• Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom… Ended
  2024-511361-11-00 Phase II/III 12 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH

Showing 73–96 of 106 trials